Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Continuous Erector Spinae Block Versus Continuous Paravertebral Block

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03768440
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : April 17, 2019
Sponsor:
Information provided by (Responsible Party):
Roland Brusseau, Boston Children’s Hospital

Brief Summary:

Overall Aim: To evaluate the efficacy of continuous erector spinae block (ESB) versus continuous paravertebral block (PVB) for postoperative analgesia in children and adolescents undergoing surgical procedures via unilateral thoracotomy.

Hypothesis: The investigators hypothesize that ESP block efficacy is not inferior to that of PVB with respect to pain control and consumed opiate equivalents at 24 hours postoperatively.


Condition or disease Intervention/treatment Phase
Pain, Postoperative Procedure: continuous erector spinae block (ESB) Procedure: continuous paravertebral block (PVB) Drug: Ropivacaine Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Continuous Erector Spinae Block Versus Continuous Paravertebral Block Following Thoracotomy: A Randomized, Controlled Non-Inferiority Study
Actual Study Start Date : April 16, 2019
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: continuous erector spinae block
An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
Procedure: continuous erector spinae block (ESB)
Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
Other Names:
  • ESB with ropivacaine
  • Naropin

Drug: Ropivacaine
Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
Other Name: Naropin

Active Comparator: continuous paravertebral block
A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
Procedure: continuous paravertebral block (PVB)
The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
Other Names:
  • PVB with ropivacaine
  • Naropin

Drug: Ropivacaine
Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
Other Name: Naropin




Primary Outcome Measures :
  1. Rescue analgesic consumption [ Time Frame: 24 hours ]
    rescue opiates (rendered as morphine equivalents/kg) given by blinded providers using standard PCA/NCA demand protocols


Secondary Outcome Measures :
  1. Pain scores [ Time Frame: 24, 48 and 72 hours ]
    Pain scores measured by the numeric rating scale (NRS: 0/none -> 10/worst)

  2. Time to perform the block in the operating room [ Time Frame: 1 hour ]
    Total time required for intervention

  3. Number of Adverse events [ Time Frame: 1 week ]
    Any intervention related (or unrelated) adverse events

  4. Rescue analgesic consumption [ Time Frame: 48 hours ]
    rescue opiates (rendered as morphine equivalents/kg) given by blinded providers using standard PCA/NCA demand protocols

  5. Rescue analgesic consumption [ Time Frame: 72 hours ]
    rescue opiates (rendered as morphine equivalents/kg) given by blinded providers using standard PCA/NCA demand protocols



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ASA I - III status, undergoing unilateral thoracotomy for either esophageal atresia related intrathoracic procedures or other non-cardiac general surgical intrathoracic procedures.

Exclusion Criteria:

  • Patients undergoing procedures including pleurodesis, pleural stripping, and decortication or other procedures with widely distributed pleural disruption.
  • Patients with severe neurodevelopmental delays.
  • Patients with previous chronic pain syndromes.
  • Patients with a history of opioid treatment at any point in the 2 months prior to surgery.
  • Lack of parental consent and/or child assent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03768440


Contacts
Layout table for location contacts
Contact: ROLAND BRUSSEAU, MD 8572184814 roland.brusseau@childrens.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Boston Children"S Hospital Recruiting
Boston, Massachusetts, United States, 02118
Contact: ROLAND BRUSSEAU, MD    857-218-4814    roland.brusseau@childrens.harvard.du   
Contact: WALID ALRAYASHI, MD    617-355-2604    walid.alrayashi@childrens.harvard.edu   
Sub-Investigator: ERIN HALPIN, RN         
Sub-Investigator: BERNIER RACHEL, RN         
Sub-Investigator: JULIAN POST, BS         
Sponsors and Collaborators
Boston Children’s Hospital
Investigators
Layout table for investigator information
Principal Investigator: ROLAND BRUSSEAU, MD Boston Children’s Hospital

Layout table for additonal information
Responsible Party: Roland Brusseau, Associate in Perioperative Anesthesia, Department of Anesthesiology, Perioperative and Pain Medicine Instructor in Anaesthesia, Havard Medical School, Boston Children’s Hospital
ClinicalTrials.gov Identifier: NCT03768440     History of Changes
Other Study ID Numbers: IRB-P00030317
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Roland Brusseau, Boston Children’s Hospital:
ropivacaine infusion
regional anesthesia
paravertebral block
erector spinae block

Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Signs and Symptoms
Ropivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents